Fudan University: Carcinoma trials

The registry lists 94 Carcinoma studies with Fudan University as lead sponsor. 33 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 1 7Phase 2 53Phase 3 18Phase 4 3No phase 18(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• TACE Plus Ivonescimab for Unresectable Non-Metastatic HCCNot yet recruitingNCT06990620Phase 1
• Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal CarcinomaNot yet recruitingNCT06957938Phase 3
• Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT06814067Phase 2
• HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of RecurrenceRecruitingNCT06812039Phase 2
• Combination of Toripalimab and JS004 Therapy for ccRCCRecruitingNCT06690697Phase 2
• Ivonescimab in the Treatment of Multiple Advanced TumorsRecruitingNCT06683846Phase 2
• AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic TherapyRecruitingNCT06494995Phase 2
• Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCCRecruitingNCT06494943Phase 1/2
• HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular CarcinomaNot yet recruitingNCT06475287Phase 2
• Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular CarcinomaNot yet recruitingNCT06441019Phase 2
• DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUCRecruitingNCT06354231Phase 2
• Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular CarcinomaRecruitingNCT06285019Phase 2
• Proteomic Guided First-line Precision Treatment of Renal Clear Cell CarcinomaRecruitingNCT06211790Phase 2
• Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 InhibitorRecruitingNCT06190782Phase 3
• CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell CarcinomaRecruitingNCT06182735Phase 1
• PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction ChemotherapyRecruitingNCT06156878Phase 2
• A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06152978Phase 2
• Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)RecruitingNCT05897268Phase 2
• Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant ChemotherapyRecruitingNCT05772208Phase 3
• Effect of Hepatectomy on the Prognosis of Patients With Nasopharyngeal Carcinoma Liver MetastasesRecruitingNCT05771025Not applicable
• A Study of IO Plus Radiotherapy in Patients With Advanced ESCC.RecruitingNCT05760391Not applicable
• Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular CarcinomaRecruitingNCT05675462Phase 1
• Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant ChemotherpyRecruitingNCT05674305Phase 3
• A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver CancerNot yet recruitingNCT05660213
• Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)RecruitingNCT05281003Phase 2
• Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular CarcinomaRecruitingNCT05057845Phase 2
• Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line ChemotherapyRecruitingNCT04978012Phase 2
• Toripalimab Based Induction Chemotherapy Followed by De-escalation Protocols in HPV-related OPSCCRecruitingNCT04867330Not applicable
• Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast CancerRecruitingNCT04790305Phase 4
• Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)RecruitingNCT04519905Not applicable
• The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)Not yet recruitingNCT04517227Not applicable
• SBRT for Oligo-metastatic Lesions After Systemic Treatment of Primary Metastatic Nasopharyngeal CarcinomaNot yet recruitingNCT04351282Not applicable
• Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal CarcinomaRecruitingNCT03790553Phase 3
• Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell CarcinomaStatus unknownNCT05759312Phase 1/2
• Peripheral Blood Neoantigen Specific T Cells Predict the Efficacy of Immunotherapy for Esophageal Squamous Cell CarcinomaStatus unknownNCT05633641
• ctDNA-based MRD Assessment in Local Advanced Esophageal CarcinomaStatus unknownNCT05426850
• Efficacy and Safety of T+A+RAD in HCCStatus unknownNCT05396937Phase 2
• Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or CarcinosarcomaStatus unknownNCT05265793Phase 2
• Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell CarcinomaStatus unknownNCT05124431Phase 2
• Tislelizumab in the Systematic Treatment of Advanced Hepatocellular CarcinomaStatus unknownNCT04996459
• PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCCStatus unknownNCT04974281Early Phase 1
• TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02)CompletedNCT04954794Phase 2
• Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT04921995Phase 2
• Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)Active, not recruitingNCT04764227Phase 2
• Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04517214Phase 2
• Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction ChemotherapyStatus unknownNCT04508829Phase 2
• Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction ChemotherapyCompletedNCT04508816Phase 2
• TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular CarcinomaCompletedNCT04297280Phase 2
• SIB in Upper Thoracic Esophageal Squamous Cell CarcinomaStatus unknownNCT04115618Phase 2
• De-escalation Protocols in HPV-related Oropharyngeal Carcinoma in Chinese PopulationsStatus unknownNCT04012502Not applicable
• Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCCCompletedNCT03985046Phase 2
• Local Therapy for Oligorecurrent and Oligometastatic Esophageal Squamous Cell CarcinomaCompletedNCT03904927Phase 2
• Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular CarcinomaStatus unknownNCT03838796Not applicable
• S-1 Combined With IMRT Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal CarcinomaCompletedNCT03668366Phase 2
• Chidamide Combined With Cisplatin in Head and Neck Adenoid Cystic Carcinoma (HNACC)CompletedNCT03639168Phase 2
• TACE Combined With RFA/MV Treatment in Hepatocellular Carcinoma Beyond Milan CriterialCompletedNCT03636620Phase 3
• Radiation-associated Carotid Artery Disease in Patients With Nasopharyngeal CarcinomaStatus unknownNCT03568032
• Apatinib for Advanced Biliary CarcinomaStatus unknownNCT03427242Phase 2
• Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 StageStatus unknownNCT03403829Phase 3
• A Study of SBRT for OligoMetastatic ESCCCompletedNCT03000816Not applicable
• Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell CarcinomaCompletedNCT02916511Phase 2
• Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular CarcinomaTerminatedNCT02748304Not applicable
• Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT02677597Phase 3
• Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell CarcinomasStatus unknownNCT02665702Phase 2
• A Study of Comparing Huachansu Plus Thoracic RT Versus RT Alone For ESCCCompletedNCT02647125Phase 2
• Efficacy Study of TACE to Treat Hepatocellular Carcinoma After OperationStatus unknownNCT02631499Phase 4
• Laparoscopic Versus Open Liver Resection for Hepatocellular CarcinomaStatus unknownNCT02526043Not applicable
• A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal CancerCompletedNCT02459457Phase 3
• Phase II Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy for Esophageal Squamous Cell CarcinomaStatus unknownNCT02384811Phase 2
• Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPCCompletedNCT02012062Phase 3
• Study of S-1 in Combination With Radiotherapy in Esophageal CancerCompletedNCT01831531Phase 2
• Role of Huachansu in Treating Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPaseStatus unknownNCT01715532Phase 2
• Adjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 ExpressionStatus unknownNCT01681446Phase 3
• Induction Chemotherapy Followed by Concurrent Radiation With Cetuximab or Cisplatin in Locally Advanced Nasopharyngeal CancerStatus unknownNCT01614938Phase 2
• A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal CarcinomaCompletedNCT01591135Phase 3
• SOX as Salvage Treatment in Nasopharyngeal CarcinomaTerminatedNCT01403259Phase 2
• Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After EsophagectomyStatus unknownNCT01402180Phase 2/3
• Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0Status unknownNCT01398449Phase 3
• A Trial Estimating The Optimal Radiation Volume Of Postsurgical Radiation For Patients With Esophageal CancerStatus unknownNCT01391572Phase 2
• Pemetrexed as Salvage Treatment in Squamous Cell Carcinoma of Head and NeckStatus unknownNCT01333696Phase 2
• Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) TherapyStatus unknownNCT01102335Phase 4
• Efficacy of Postoperative Adjuvant Treatments for Hepatocellular Carcinoma With Portal Vein Tumor ThrombosisStatus unknownNCT01033578Not applicable
• Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver CancerStatus unknownNCT00999843Phase 1/2
• Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric CancerCompletedNCT00970138Phase 2/3
• Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular CarcinomaStatus unknownNCT00921531Phase 3
• Radiation Dose Escalation Study for Advanced Liver CancerCompletedNCT00848094Phase 1
• The Efficiency of Postoperative Interferon-alpha Treatment in p48 Positive Patients With Hepatocellular CarcinomaWithdrawnNCT00838968Not applicable
• Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma (NPC)Status unknownNCT00817583Phase 2
• Study of Concurrent Chemotherapy and Radiotherapy for Stage II Nasopharyngeal CarcinomaStatus unknownNCT00817258Phase 2
• Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage Ⅲ Nasopharyngeal CarcinomaStatus unknownNCT00816855Phase 2
• Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage ⅣAB Nasopharyngeal CarcinomaStatus unknownNCT00816816Phase 2
• Songyou Granule and Transarterial Chemoembolization for Hepatocellular CarcinomaStatus unknownNCT00805896Phase 2
• Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative ResectionStatus unknownNCT00561522Phase 2/3
• Study of Thymopentin in Patients After Curative Resection of Small Hepatocellular CarcinomaStatus unknownNCT00460681Phase 3